Protein transduction domain · Dishevelled binding motif
PTD-DBM
Preclinical Usually topical
What it is
PTD-DBM is a research peptide built from a cell-penetrating “protein transduction domain” fused to a Dishevelled-binding motif. Papers from Korean groups studied it as a way to block CXXC5, a negative regulator of Wnt/β-catenin, in hair-growth models.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A topical research peptide aimed at the Wnt path that hair follicles use to stay in a growth phase.
- People use it on the scalp hoping for thicker-looking hair or less shedding, often next to GHK-Cu or minoxidil-class routines.
- Evidence is early and mostly mechanistic / small reports, not big baldness trials.
- It is a leave-on scalp idea, not an injection peptide in most protocols people cite.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
CXXC5 binds Dishevelled and damps Wnt signaling in the follicle. Occupying that interaction is meant to restore Wnt activity, which in mice associated with anagen entry and hair-shaft growth. This is pathway pharmacology, still early.
Possible side effects / caveats
Human safety package is essentially absent. Wnt gain-of-function is not a trivial lever (development, oncogenic signaling in other tissues). Topical use confines exposure better than systemic use; that is a reason most catalog talk stays on the scalp, not an injection protocol.
Protocol ranges
| Source tier | Amount | Cadence | Notes |
|---|---|---|---|
| Preclinical | Topical application in animal papers | Repeated local use | Concentrations are study-specific |
| Cited research serums | Low-percent leave-on solutions | Daily scalp application in community writeups | No accepted human milligram dose |